GLP-1 Agonists Market Size, Share & Trends Analysis Report By Product (Branded GLP-1 Agonists, Dual / Triple, Biosimilars & Generic GLP-1 Agonists Agonists), By Indication (Type 2 Diabetes Mellitus, Obesity / Overweight Management, Cardiovascular & Metabolic Related Indications, Other Emerging Indications (e.g., NASH, Alzheimers-related)), By Route of Administration, By Distribution Channel, By Region and By Segments Forecasts, 2025-2034 GLP-1 Agonists Market Size is valued at USD 43.1 Bn in 2024 and is predicted to reach USD 260.1 Bn by the year 2034 at an 19.9% CAGR during the forecast period for 2025-2034
That includes younger patients with family histories of heart attack and older patients whove had diabetes for years
That distinction matters when evaluating sourcing options, and it means the availability situation for Canadians is different from the US, where Retatrutide in particular remains in Phase 3 clinical trials
This cream, cruelty-free and made with premium ingredients in a GMP-certified USA facility, can stand alone for a simplified routine or be paired with our face and neck serum for enhanced benefits
Nausea, vomiting, diarrhea, and constipation remain the most common issues
CONTRAINDICATIONS: Personal/family history of MTC Multiple endocrine neoplasia syndrome type 2 Prior serious hypersensitivity to the active component or any of the ingredients Ozempic (injection and tablets), Rybelsus tablets, and Wegovy tablets: Safety and efficacy have not been established in patients younger than 18 years